Atlas Trials

Fate Therapeutics

24 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Fate Therapeutics

RecordFirmDate
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis (NCT07570862)Fate Therapeutics2026-07-27
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors (NCT07216105)Fate Therapeutics2025-11-04
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease (NCT06308978)Fate Therapeutics2024-03-28
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors (NCT06241456)Fate Therapeutics2024-01-05
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) (NCT05950334)Fate Therapeutics2023-11-16
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma (NCT05934097)Fate Therapeutics2022-12-01
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors (NCT05395052)Fate Therapeutics2022-05-31
FT576 in Subjects With Multiple Myeloma (NCT05182073)Fate Therapeutics2021-11-10
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors (NCT05069935)Fate Therapeutics2021-10-15
FT819 in Subjects With B-cell Malignancies (NCT04629729)Fate Therapeutics2021-07-12
FT538 in Subjects With Advanced Hematologic Malignancies (NCT04614636)Fate Therapeutics2020-10-17
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors (NCT04551885)Fate Therapeutics2020-09-07
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies (NCT04245722)Fate Therapeutics2020-03-19
Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy (NCT04093622)Fate Therapeutics2019-10-04
FT516 in Subjects With Advanced Hematologic Malignancies (NCT04023071)Fate Therapeutics2019-10-04
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy (NCT04106167)Fate Therapeutics2019-06-11
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (NCT03841110)Fate Therapeutics2019-02-15
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors (NCT03319459)Fate Therapeutics2018-01-18

Track Fate Therapeutics automatically

Every clearance here is in the API, with alerts when new ones post.